CN113018433A - Immune medicine and application thereof in tumor immunotherapy - Google Patents
Immune medicine and application thereof in tumor immunotherapy Download PDFInfo
- Publication number
- CN113018433A CN113018433A CN202110263141.2A CN202110263141A CN113018433A CN 113018433 A CN113018433 A CN 113018433A CN 202110263141 A CN202110263141 A CN 202110263141A CN 113018433 A CN113018433 A CN 113018433A
- Authority
- CN
- China
- Prior art keywords
- aptamer
- nucleic acid
- protein
- dna
- specific binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 238000009169 immunotherapy Methods 0.000 title claims abstract description 27
- 108091023037 Aptamer Proteins 0.000 claims abstract description 76
- 210000004027 cell Anatomy 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 39
- 230000009870 specific binding Effects 0.000 claims abstract description 36
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 35
- 108091008324 binding proteins Proteins 0.000 claims abstract description 35
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 108091008104 nucleic acid aptamers Proteins 0.000 claims abstract description 14
- 230000027455 binding Effects 0.000 claims abstract description 12
- 210000002865 immune cell Anatomy 0.000 claims abstract description 11
- 238000001727 in vivo Methods 0.000 claims description 7
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 5
- 102100034256 Mucin-1 Human genes 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 230000004565 tumor cell growth Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 23
- 239000002086 nanomaterial Substances 0.000 abstract description 22
- 230000008685 targeting Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000005859 cell recognition Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 74
- 239000002105 nanoparticle Substances 0.000 description 28
- 210000001744 T-lymphocyte Anatomy 0.000 description 24
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 23
- 102000010970 Connexin Human genes 0.000 description 15
- 108050001175 Connexin Proteins 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 108020001507 fusion proteins Proteins 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 230000002147 killing effect Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 6
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 4
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 108700041430 link Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241001664991 Duck circovirus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention firstly provides an immune medicament, which is a dual-specificity immune medicament comprising a specific binding protein and a nucleic acid aptamer, wherein the specific binding protein and the nucleic acid aptamer are connected in a direct or indirect mode, the specific binding protein is of a protein structure, the nucleic acid aptamer is of a nucleic acid structure, the specific binding protein is used for being specifically combined with an immune cell receptor or a target cell receptor, and the corresponding nucleic acid aptamer is used for being specifically combined with the target cell receptor or the immune cell receptor. The invention also provides application of the immune medicament in tumor immunotherapy. The invention broadens the types of immunotherapy drugs, and the current bispecific antibody is evolved into a chimeric form with DNA involved. The invention takes the aptamer as a target cell recognition element, and can be assembled into a nano structure in a programmed way by virtue of the advantages of wide targeting range, so as to realize targeting of various tumor cells and improve the binding affinity and specificity of the aptamer and the tumor cells.
Description
Technical Field
The invention relates to the technical field of tumor immunotherapy drugs, and particularly provides a novel immunotherapy drug for mediating T cell to kill tumor cells in a targeted manner, a preparation method thereof and application thereof in tumor immunotherapy.
Background
Cancer immunotherapy can activate the immune system of a patient to prevent immune evasion by cancer, and has great potential in reducing cancer metastasis and recurrence for a long time. Unlike traditional chemotherapy or radiotherapy, tumor immunotherapy has greater selectivity and lower toxicity in tumor therapy, while providing long-term immunity through immunological memory. Recent studies have shown that T cells can redirect and eliminate tumors by bispecific molecules that bind tumor-specific antigens. Among them, people have attracted special attention because of the advantage that Bispecific T-cell engage (BiTE) antibody mediated killing can bypass MHC restriction to selectively kill tumor cells. BiTE is essentially a single polypeptide chain comprising single chain (sc) Fv domains of two different antibodies, one of which is designed to recognize CD3e expressed on any T cell, and the other of which is designed to bind a tumor-associated antigen expressed by a tumor cell. Despite their remarkable success, since BiTE belongs to the protein class of drugs, bites for the treatment of different tumor cells must be genetically engineered by means of existing DNA sequences, a process which is not only time and labor consuming but also whose stability and activity cannot be guaranteed. Meanwhile, customized medical treatment cannot be quickly realized according to the actual condition of a patient. In addition, the in vivo is a multicellular environment, the types of molecules on the surface of tumor cells are the same as those on the surface of normal cells, and only the difference of expression amount exists, so that the composition of the BiTE structure is fixed at present, so that the BiTE structure can kill the normal cells in the immunotherapy process, and certain side effects exist. From this point of view, aptamers (aptamers) can solve the problems of the existing BiTE. Aptamers are called "chemical antibodies" and are considered to be an ideal choice for targeted therapy of tumors because of their small size, ease of preparation, and good targeting properties. Thereby expanding the cancer treatment range and accelerating the drug generation and development process. In addition, the aptamer can be rapidly assembled into a DNA nano structure with other DNA in a test tube by the base complementary pairing principle. DNA nanostructures are widely used in the biomedical field due to their programmability, ease of modification, and high biocompatibility. And different structures of the antigen can combine different numbers of aptamers, thereby improving the tumor recognition capability and reducing the side effect of immunotherapy.
Therefore, there is an urgent need in the art to develop an immunopharmaceutical that recognizes tumor cell surface molecules using nucleic acids, which is used to solve the problems of time and labor consuming development of the existing immunotherapy, limited subjects and side effects.
Disclosure of Invention
In the invention, the aptamer is used for replacing an antibody structure domain in the current BiTE to identify the molecules on the surface of tumor cells, and the antibody-nucleic acid chimera obtained by research and development can solve the problems in the prior art as a novel bispecific drug.
Therefore, the invention firstly provides an immune medicament, the immune medicament is a dual-specificity immune medicament (1) comprising a specific binding protein (11) and a nucleic acid aptamer (12), and the specific binding protein (11) and the nucleic acid aptamer (12) are connected in a direct or indirect mode, the specific binding protein (11) is a protein structure, the nucleic acid aptamer (12) is a nucleic acid structure, the specific binding protein (11) is used for specifically binding with an immune cell receptor or a target cell receptor, and correspondingly, the nucleic acid aptamer (12) is used for specifically binding with the target cell receptor or the immune cell receptor.
In a specific embodiment, a covalent linking protein (13) and a covalent linking DNA (14) are linked between the specific binding protein (11) and the aptamer (12), the covalent linking protein (13) is linked to the specific binding protein (11), the covalent linking DNA (14) is linked directly or indirectly to the aptamer (12), and the covalent binding between the covalent linking protein (13) and the covalent linking DNA (14).
In a particular embodiment, a linking structure is also linked between the covalently linked DNA (14) and the aptamer (12), the linking structure also being composed of nucleotides.
In a particular embodiment, the covalent linking protein (13) is a HUH family protein, preferably a DCV protein.
In a specific embodiment, the immune drug comprises one aptamer (12) or a plurality of same or different aptamers (12), and preferably the immune drug comprises 3-100 same or different aptamers.
In a specific embodiment, the specific binding protein (11) is α CD 3.
In a specific embodiment, the aptamer (12) is one or more of sgc8, TE02, SYL3C, MUC1 and C-MET.
In a specific embodiment, the covalently attached DNA (14) has the sequence aagtattaccagaaa.
The invention also provides application of the immune medicament in tumor immunotherapy.
In a specific embodiment, the immunopharmaceutical is targeted to inhibit tumor cell growth in vivo.
The invention also provides a preparation method of the immune medicament, the immune medicament is a dual-specificity immune medicament (1) comprising the specific binding protein (11) and the aptamer (12), and the specific binding protein (11) and the aptamer (12) are indirectly connected, the specific binding protein (11) is a protein structure, the aptamer (12) is a nucleic acid structure, the specific binding protein (11) is used for specifically binding with an immune cell receptor or a target cell receptor, and correspondingly, the aptamer (12) is used for specifically binding with the target cell receptor or the immune cell receptor; a covalent linking protein (13) and a covalent linking DNA (14) are connected between the specific binding protein (11) and the aptamer (12), the covalent linking protein (13) is directly or indirectly connected with the specific binding protein (11), the covalent linking DNA (14) is directly or indirectly connected with the aptamer (12), and the covalent binding is formed between the covalent linking protein (13) and the covalent linking DNA (14); the preparation method comprises the following steps of,
step A: preparing a fusion protein containing the specific binding protein (11) and the covalent linking protein (13);
and B: preparing a nucleic acid construct comprising said aptamer (12) and covalently linked DNA (14);
step A and step B can be carried out simultaneously or in any sequence;
and C: and (C) incubating the fusion protein prepared in the step (A) and the nucleic acid structure obtained in the step (B) together, and enabling the covalent link protein (13) and the covalent link DNA (14) to be covalently bound to obtain the immune drug.
In a specific embodiment, the nucleic acid sequence of the fusion protein is first synthesized in a whole gene and a recombinant plasmid is constructed, and then the active fusion protein is expressed by escherichia coli pronucleus.
In a specific embodiment, after step a, the purification of the resulting fusion protein is further included.
In a particular embodiment, in step B, the nucleic acid structure further comprises a linking structure for linking the aptamer (12) and covalently linking the DNA (14), the linking structure also consisting of nucleotides.
In a specific embodiment, the nucleic acid structure comprises any one of a single-stranded aptamer, a Y-type DNA nanoparticle and a dendritic DNA nanoparticle, wherein the single-stranded aptamer comprises 1 aptamer (12), the Y-type DNA nanoparticle comprises 2 aptamers (12), the dendritic DNA nanoparticle comprises 3-100 aptamers (12), and the aptamers (12) contained in the Y-type DNA nanoparticle and the dendritic DNA nanoparticle are the same or different.
In a specific embodiment, the Y-shaped DNA nanoparticles are prepared by an enzyme-free self-assembly process, and the dendritic DNA nanoparticles are synthesized in vitro by a polymeric chain reaction.
In a specific embodiment, the incubation method is to mix the fusion protein prepared in step a and the nucleic acid structure obtained in step B, incubate the mixture at 36-38 ℃ for more than 10 minutes to obtain the immune drug, and preferably store the obtained immune drug at 2-8 ℃ for later use.
In a specific embodiment, the covalently linked protein (13) is a HUH family protein, preferably a DCV protein, and the covalently linked DNA (14) has the sequence aagtattaccagaaa.
In a specific embodiment, the specific binding protein (11) is α CD 3.
In a specific embodiment, the aptamer (12) is one or more of sgc8, TE02, SYL3C, MUC1 and C-MET.
The invention has at least the following beneficial effects:
1) the invention prepares the bispecific antibody-nucleic acid chimera by covalently combining the antibody single-chain-DCV fusion protein and the nucleic acid aptamer, widens the types of immunotherapy drugs, and develops the current bispecific antibody into a chimeric form with DNA participation.
2) The invention uses the antibody-nucleic acid chimera to mediate T cells to kill tumor cells, the generation process of the chimera overcomes the defect that the traditional bispecific antibody must be subjected to genetic engineering, shortens the synthesis and preparation time of the immunopharmaceuticals, and reduces the production cost.
3) The invention takes the aptamer as a target cell recognition element, depends on the advantages of more targets of the aptamer and capability of being assembled into a nano structure in a programmed manner, has various tumor recognition types, improves the binding affinity and specificity with tumor cells, and enlarges the recognition range of different tumor specificities.
4) The invention is based on the base complementary pairing principle to rapidly assemble the DNA nano structure with a specific structure and a specific valence state. Chimeras formed by different DNA nanostructures and antibody single chains can achieve different therapeutic effects. It is possible to make the reagent customized.
Drawings
FIG. 1 is a schematic diagram of the binding of the immunopharmaceutical of the present invention to T cells (i.e., immune cells) and target cells (i.e., tumor cells).
FIG. 2 shows the effect of the antibody-sgc 8 aptamer chimera on tumor killing measured at the cellular level.
FIGS. 3-4 are graphs demonstrating the universality of the application of the antibody-nucleic acid chimera in the field of immunotherapy.
FIGS. 5 to 8 are schematic diagrams of in vivo targeting and killing of tumor cells by the antibody-nucleic acid chimera. In which, fig. 5 and 6 are statistics of continuously measured tumor size, and fig. 7 and 8 are statistics of continuously measured mouse body weight.
In fig. 1: immune drug 1, specific binding protein 11, aptamer 12, covalent link protein 13, covalent link DNA14, T cell 2, T cell receptor 21, target cell 3, target cell receptor 31.
The features and advantages of the present invention will be further understood from the following detailed description taken in conjunction with the accompanying drawings. The examples provided are merely illustrative of the method of the present invention and do not limit the remainder of the disclosure in any way.
Detailed Description
In order that the invention may be more fully understood, a more particular description of the invention will now be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. However, the invention may be implemented in many different combinations and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
The invention provides a novel immune medicament for tumor immunotherapy, which comprises two modules: the two modules can be covalently connected to form a chimera, and the chimera can mediate specific recognition of T cells and target cells and inhibit growth of tumor cells in a targeted manner in vitro and in vivo. The antibody-nucleic acid chimera has the structure shown in FIG. 1.
The invention also aims to provide a preparation method of the antibody-nucleic acid chimera, which comprises the following steps: the antibody is illustrated by a DCV-alpha CD3 fusion protein;
firstly), preparing an antibody;
1) recombinant plasmids containing antibody sequences, such as pET28 a-DCV-alpha CD3, were synthesized in their entirety.
2) Prokaryotic expression of active DCV-alpha CD3 fusion protein (i.e., fusion protein formed by the linkage of specific binding protein 11 and covalent linking protein 13).
Preferably, the DCV- α CD3 fusion protein expression purification method is as follows: pET28 a-DCV-alpha CD3 recombinant plasmid heat shock transformation Escherichia coli BL21(DE3) competence, 1mM IPTG induced its expression of target protein, collection of bacterial liquid, after ultrasonication, NI column purification of 6 His-DCV-alpha CD3 fusion protein.
II) preparing nucleic acid;
nucleic acids include three forms: single-stranded aptamers, Y-type DNA nanoparticles and dendritic DNA nanoparticles.
Alternatively, the single-chain aptamer of the invention is exemplified by sgc8 aptamer, and the sequence thereof is as follows:
aagtattaccagaaaaaaaaaaaaaaaATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGA are provided. Wherein aagtattaccagaaaaaaaaaaaaaaa is the covalently linked DNA of the present invention (14).
The number of aptamers (aptamers) connected to the Y-type DNA nanoparticles is 2, and the DNA nanoparticles can be the same or different. The Y-type DNA nano-particle is assembled by three nucleic acid chains, and the sequence of the Y-type DNA nano-particle is as follows:
Y1-DCV:aagtattaccagaaa TTTTTGAC CGA TGG ATG ACT TAC GAC GCA CAA GGA GAT CAT GAG;
Y2-sgc8:ATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGATTTTTGACCGA TGG ATG ACC TGT CTG CCT AAT GTG CGT CGT AAG;
Y3-sgc8:ATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGATTTTTGACCGA TGG ATG ACT CAT GAT CTC CTT TAG GCA GAC AGG。
wherein aagtattaccagaaa is the covalently linked DNA of the present invention (14).
The number n of the connected nucleic acid aptamers in the dendritic DNA nano-particles is less than 100, the specific number n can be any integer, and the DNA nano-particles can be the same or different. The structure of the dendritic DNA nanoparticles for assembling is assembled by five nucleic acid chains, and the sequence is as follows:
H1:TTAACCCACGCCGAATCCTAGACTCAAAGTAGTCTAGGATTCGGCGTGAAA AAGTGAGCACGGACG;
H2:GACGTGCAGGCTGTTTAAAGTCTAGGATTCGGCGTGGGTTAACACGCCGA ATCCTAGACTACTTTG;
Sgc8c-SH2:CAGCCTGCACGTCATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGA;
DNA1(C1)NC:CGTCCGTGCTCAC;
DCV Initiator(I):aagtattaccagaaaAGTCTAGGATTCGGCGTGGGTTAA。
wherein the sequence aagtattaccagaaa is a DCV protein targeting DNA sequence, namely, the covalently linked DNA (14) of the present invention, and is used for covalently linking an antibody to a nucleic acid structure, namely, the covalently linked DNA (14) of the present invention.
Thirdly), preparing an antibody-aptamer chimera;
and (3) incubating the antibody in the step one) and the nucleic acid in the step two) together to obtain the antibody-nucleic acid chimera.
The invention also provides application of the antibody-nucleic acid chimera in tumor immunotherapy.
In one embodiment of the invention, the effect of the bispecific antibody-nucleic acid chimera sgc 8-DCV-alpha CD3 on mediated T cell killing of tumor cells is detected in vitro, and the cell level is detected by using a CCK8 method to detect the target killing effect on CCRF-CEM human acute lymphoblastic leukemia cells. As a result: the prepared sgc 8-DCV-alpha CD3 chimera has the capacity of mediating T cells to kill tumor cells, and the killing effect is gradually enhanced along with the increase of the drug concentration of the sgc 8-DCV-alpha CD3 chimera.
In one embodiment of the present invention, sgc8 in the above embodiment is replaced by an antibody-nucleic acid chimera prepared from any other aptamer (in this embodiment, TE02, SYL3C, MUC1 and C-MET), and the chimera is tested at the cellular level for its killing effect on different types of tumor cells by the CCK8 method. The results show that: chimeras connected with different aptamers can mediate T cells to kill tumor cells, and the method has universality in the field of immunotherapy.
In one embodiment of the present invention, the effect of antibody-aptamer nanostructure chimeras in mediating T cell killing in vitro was studied. The antibody-aptamer nano-structure chimera is used as a medicine, and the cell level is used for detecting the breast cancer targeted killing effect of the antibody-aptamer nano-structure chimera on MCF-7 human by using a CCK8 method. The result shows that the prepared antibody-dendritic aptamer nanostructure chimera has the best effect of mediating T cells to kill tumor cells, and the antibody-Y aptamer nanostructure is adopted. antibody-Y aptamer nanostructures represent bivalent DNA nanoparticles. In addition to the Y-shaped structure in this embodiment, other nanostructures to which a defined number of aptamers are attached may be used. In addition dendritic DNA nanostructures represent DNA nanostructures synthesized in vitro by the polymer chain reaction.
In one embodiment of the invention, a nude mouse model is utilized to perform a targeting experiment of an in vivo antibody-nucleic acid chimera on nude mouse subcutaneous tumor-bearing CEM, and the sgc8 aptamer is taken as an example to explore the tumor immunotherapy effect of the antibody-nucleic acid chimera with different structures. Immunotherapy effects were reflected by continuous measurement of tumor size and measurement of mouse body weight. The results show that the tumor of the experimental group injected with the antibody-nucleic acid chimera is significantly smaller than that of the control group. In the experimental group, injection of the antibody-dendritic aptamer nanostructure chimera significantly inhibited tumor growth, followed by the antibody-Y aptamer nanostructure chimera. The immunotherapy effect can be improved by constructing the DNA nanoparticles with different structures, and a new idea is provided for tumor therapy.
In summary, the antibody-nucleic acid chimera provided by the present invention is a novel immunotherapeutic drug, which is first applied to T cell-mediated immunotherapy. The medicine comprises an antibody module and a nucleic acid module, wherein the antibody module can be any antibody single chain capable of identifying immune cell surface molecules, and the nucleic acid module can also be any aptamer capable of identifying tumor cell surface molecules. In addition, the invention constructs DNA nano particles with different structures on the basis that the antibody can form chimera with nucleic acid, and applies the functionalized DNA nano particles to the field of immunotherapy. The DNA nano-particle comprises a nano-structure connected with a specific number of aptamers (such as the aptamer number n of a Y-shaped structure is 2 and the like) and a nano-structure of a plurality of aptamers formed by polymerization chain Hybridization (HCR) (such as the aptamer number n of a dendritic structure is less than 100), wherein multivalent DNA nano-particles can be the same DNA sequence or different DNA sequences.
The bispecific immunopharmaceutical in the present invention means that the immunopharmaceutical has specificity to both T cells (immune cells) and target cells (tumor cells). The bispecific immune drug used for connecting T cells and target cells in the prior art is either protein or nucleic acid in both modules, and the invention firstly proposes a bispecific immune drug comprising a protein module and a nucleic acid module.
The preparation method of the immune medicine comprises the following steps: in 2018, the covalent binding of covalent connexin 13 and covalent connexin 14 is reported, the invention prepares a covalent connexin 13 according to the literature, then prepares a conjugate of specific binding protein 11 and covalent connexin 13, and connects covalent connexin 13-matched covalent connexin DNA14 and aptamer 12 to form a nucleic acid structure (the nucleic acid structure can be customized by a nucleic acid manufacturer), and then uses the covalent binding of covalent connexin 13 and covalent connexin DNA14 to obtain the whole immune drug containing specific binding protein 11, aptamer 12, covalent connexin 13 and covalent connexin DNA14, and the structure of the immune drug sequentially comprises specific binding protein 11, covalent connexin 13, covalent connexin DNA14 and aptamer 12 from one end to the other end. In the present invention, the covalent binding protein 13 may be specifically a HUH protein, more specifically a DCV protein, but may be a protein belonging to many families other than HUH, and can covalently bind to DNA.
The specific binding protein 11 of the present invention may bind to a receptor of a T cell, in which case the aptamer 12 binds to a receptor of a target cell, or the reverse, in which the aptamer 12 binds to a receptor of a T cell, and the specific binding protein 11 binds to a receptor of a target cell.
The aptamer 12 of the present invention is indispensable, and the aptamer is essentially nucleic acid, and ordinary DNA is also nucleic acid, but ordinary DNA cannot be used in the present invention because it does not have the ability of the aptamer to specifically recognize a receptor.
In addition, because it is difficult to directly connect the common protein with the common nucleic acid chain, the specific binding protein 11 and the aptamer 12 are connected by specifically adopting the covalent connexin 13 and the covalent connexin DNA14 in the invention, the covalent connexin 13 reported in the literature is a DCV protein of HUH family, which belongs to a protein member of duck circovirus, compared with other similar proteins, such as: PCV (porcine virus) has the highest efficiency of connecting DCV with DNA, so the corresponding DCV protein is expressed according to the literature in the invention.
Example 1
This example is the preparation of DNA nanoparticles.
One, single-chain aptamers.
A DCV protein recognition sequence named DCV-aptamer was added to the 5' end of the published aptamer sequence. The nucleic acid synthesis mechanism sent to the Shanghai synthesizes a single-stranded aptamer.
Secondly, preparing Y-type DNA nano particles.
1, three nucleotide chains are ordered: YA-sgc8, Yb-DCV and YC-sgc 8.
2, synthesizing Y-type DNA nano-particles: the Y-shaped DNA macromolecules are prepared by an enzyme-free self-assembly process. First, a Y-junction scaffold (Y-DNA) was prepared as a building block. In the experiment, the three oligonucleotide chains contain the aptamer and the target sequence of DCV protein (YA-sgc8, Yb-DCV, YC-sgc8 sequence), which is PBS-MgCl2Solution (10mM, pH 7.4, containing 150mM NaCl and 2mM MgCl)2) Dissolved at a concentration of 10 mM. The DNA mixed solution is heated in boiling water for 5min, then slowly cooled to room temperature, and kept in a refrigerator at 4 ℃ for later use.
Thirdly, preparing the dendritic DNA nano particles.
1, ordering the five nucleotide chains required for building the structure, namely H1, H2, sgc8C-SH2, DNA1(C1) NC and DCV Initiator (I) as described above.
2, using PBS-MgCl to make the above-mentioned five chains2The solution was dissolved and diluted to a final concentration of 10mM by first mixing and diluting H1, H2, sgc8C-SH2 and DNA1(C1) NC in equal amounts to a final concentration of 20. mu.M, heating the DNA mixture solution in boiling water for 5min, and then slowly cooling to room temperature. After cooling, 4. mu.M of DCV initiator (I) was added to the DNA mixture and the mixture was allowed to stand at 37 ℃ for overnight reaction. And placing the assembled DNA nano particles in a refrigerator at 4 ℃ for later use.
Example 2
This example is the preparation of an antibody-nucleic acid chimera.
The DCV-alpha CD3 fusion protein was added to DCV-sgc8 aptamer in equal amounts and mixed, and cultured at 37 ℃ for 15 min. Then stored at 4 ℃ for later use.
Example 3
This example is the application and detection of antibody-nucleic acid chimera in vitro and in vivo for tumor targeted killing. An example of the preparation of an aptamer-DCV-alpha CD3 chimera is DCV-sgc8 (aptamer of human acute lymphoblastic leukemia).
Firstly, a cell level CCK8 method detects that the aptamer-DCV-alpha CD3 chimera mediates the target killing effect of T cells.
1, CCRF-CEM cells (5% FBS +1640) and PBMC cells (5% FBS +1640+ IL2) which were well pre-fed;
2, taking the CEM cells (2 x 10)4Individual cells) and PBMC cells (human peripheral blood mononuclear cells) (1 x 10)5Individual cells) and various concentrations of sgc 8-DCV-. alpha.CD 3 were incubated at 37 ℃ for 24 hours.
3, detecting the reduction amount of the cell number of the sgc 8-DCV-alpha CD3 mediated T cell targeting lysis CEM cells by using a CCK-8 kit (cat No. C0039, Byunnan), thereby judging the killing effect. CCRF-CEM human acute lymphoblastic leukemia was plated per well in 96-well plates. The control group was set up to include only T cells and CEM cells (human acute lymphoblastic leukemia cells) as well as the negative cells Ramos. Simultaneous assessment of tumor cell and effector cell number ratioInfluence of (2 x 10) CEM cells4Individual cells) with different numbers of PBMC cells (0, 1 x 10)5,2*105) And 100nm sgc 8-DCV-. alpha.CD 3 chimera incubated at 37 ℃ for 24 hours.
After 4, 24h, 20ul CCK-8 solution was added per well. After incubation at 37 ℃ for 2 hours, the absorbance at 570nm was measured using Bio-Tek, SYNERGYMx. The cytotoxicity was calculated as cell killing rate (%) ═ 100 (experimental value-experimental low control)/(high control-low control).
As a result: the novel immune drug prepared by the method (taking sgc 8-DCV-alpha CD3 as an example) has the capacity of mediating T cells to kill tumor cells, and the killing effect is gradually enhanced along with the increase of the concentration of sgc 8-DCV-alpha CD 3. As shown in fig. 2. In FIG. 2, CEM is human acute lymphocytic leukemia cell, and Ramos is negative cell.
Fig. 3 and 4 are both to verify the universality of the application of the antibody-nucleic acid chimera in the field of immunotherapy. NC, sgc8, TE02, SYL3C, MUC1 and C-MET belong to aptamers, MCF-7 in FIG. 4 is a human breast cancer cell, Hela is a cervical cancer cell, HepG2 cell is a liver cancer cell, LO2 is a human normal liver cell, and SH-SY5Y is a human neuroblastoma cell.
Secondly, the targeted killing effect of sgc 8-DCV-alpha CD3 chimera on CCRF-CEM human acute lymphoblastic leukemia is detected at the living body level.
1, subcutaneous tumor-bearing CCRF-CEM in 4-6 weeks old female nude mice on day 0, 1 x 106One/one;
2, on day 7, tumor-bearing nude mice were randomly divided into two groups, a group a was a PBS control group, a group b was an injection T cell group, and a group b was subdivided into 5 groups: a blank control group, a DCV-alpha CD3 antibody control group, an sgc 8-DCV-alpha CD3 experimental group, a bivalent sgc 8-DCV-alpha CD3 experimental group and a multivalent sgc 8-DCV-alpha CD3 experimental group.
3, measuring the size of the tumor once every 2 days by using a vernier caliper and recording the size of the tumor in the whole experiment;
4, recording the weight of the tumor-bearing nude mice in the whole experiment process;
5, the experiment was ended up to 32 days.
The experimental results are shown in FIGS. 5 to 8. Among them, fig. 5 and 6 are statistical results of continuously measuring tumor sizes, and the results show that the tumors of the sgc 8-DCV-alpha CD3 injection group are significantly smaller than those of the protein injection only group. Meanwhile, the multivalent sgc 8-DCV-alpha CD3 (dendritic DNA nanostructure) experimental group has the tumor remarkably smaller than that of the bivalent sgc 8-DCV-alpha CD3 (Y-type DNA nanostructure) experimental group and sgc 8-DCV-alpha CD3 (linear single-chain) experimental group. The improvement of the valence state can improve the immunotherapy effect. Fig. 7 and 8 are statistical results of continuously measuring the body weight of tumor-bearing nude mice, and the results show that the injected medicament does not affect the life activities of the tumor-bearing nude mice.
In conclusion, the antibody-nucleic acid chimera constructed by the invention can mediate T cells to kill tumors in a targeted manner when being used as a medicament. And the immunotherapy effect can be customized and adjusted by building a DNA nano structure in vitro.
The foregoing is a more detailed description of the invention in connection with specific preferred embodiments and it is not intended that the invention be limited to these specific details. For those skilled in the art to which the invention pertains, several simple deductions and substitutions can be made without departing from the spirit of the invention, and all shall be considered as belonging to the protection scope of the invention.
Sequence listing
<110> university of Hunan
<120> immune medicine and application thereof in tumor immunotherapy
<130> 2021
<160> 11
<170> SIPOSequenceListing 1.0
<210> 1
<211> 15
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
<210> 2
<211> 68
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
aagtattaccagaaaaaaaaaaaaaaaATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGA 68
<210> 3
<211> 27
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
aagtattaccagaaaaaaaaaaaaaaa 27
<210> 4
<211> 59
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
aagtattaccagaaa TTTTTGAC CGA TGG ATG ACT TAC GAC GCA CAA GGA GAT CAT GAG 59
<210> 5
<211> 85
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGATTTTTGACCGA TGG ATG ACC TGT CTG CCT AAT GTG CGT CGT AAG 85
<210> 6
<211> 85
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
ATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGATTTTTGACCGA TGG ATG ACT CAT GAT CTC CTT TAG GCA GAC AGG 85
<210> 7
<211> 66
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
TTAACCCACGCCGAATCCTAGACTCAAAGTAGTCTAGGATTCGGCGTGAAA A AGTGAGCACGGACG 66
<210> 8
<211> 66
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
GACGTGCAGGCTGTTTAAAGTCTAGGATTCGGCGTGGGTTAACACGCCGAAT CCTAGACTACTTTG 66
<210> 9
<211> 54
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
CAGCCTGCACGTCATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGA 54
<210> 10
<211> 13
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
<210> 11
<211> 39
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
aagtattaccagaaaAGTCTAGGATTCGGCGTGGGTTAA 39
Claims (10)
1. An immunopharmaceutical which is a bispecific immunopharmaceutical (1) comprising a specific binding protein (11) and a nucleic acid aptamer (12), and the specific binding protein (11) and the nucleic acid aptamer (12) are linked by direct or indirect means, the specific binding protein (11) is a protein structure per se, the nucleic acid aptamer (12) is a nucleic acid structure per se, the specific binding protein (11) is used for specific binding to an immune cell receptor or a target cell receptor, and correspondingly, the nucleic acid aptamer (12) is used for specific binding to a target cell receptor or an immune cell receptor.
2. The immunopharmaceutical according to claim 1, wherein a covalent linking protein (13) and a covalent linking DNA (14) are linked between the specific binding protein (11) and the aptamer (12), the covalent linking protein (13) is linked to the specific binding protein (11), the covalent linking DNA (14) is linked directly or indirectly to the aptamer (12), and the covalent binding between the covalent linking protein (13) and the covalent linking DNA (14).
3. The immunopharmaceutical of claim 2, wherein a linking structure is further linked between the covalently linked DNA (14) and the aptamer (12), the linking structure also consisting of nucleotides.
4. The immunopharmaceutical according to claim 2, wherein the covalent linking protein (13) is a HUH family protein, preferably a DCV protein.
5. The immunopharmaceutical according to claim 1, wherein the immunopharmaceutical comprises one aptamer (12) or a plurality of same or different aptamers (12), preferably the immunopharmaceutical comprises 3-100 same or different aptamers.
6. The immunopharmaceutical of claim 1, wherein the specific binding protein (11) is α CD 3.
7. The immunopharmaceutical of any one of claims 1-6, wherein the aptamer (12) is one or more of sgc8, TE02, SYL3C, MUC1, and C-MET.
8. The immunopharmaceutical of claim 1, wherein the covalently linked DNA (14) has a sequence of aagtattaccagaaa.
9. Use of an immunopharmaceutical according to any one of claims 1-8 in the immunotherapy of tumors.
10. The use of claim 9, wherein the immune drug is targeted to inhibit tumor cell growth in vivo.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110263141.2A CN113018433B (en) | 2021-03-11 | 2021-03-11 | Immune medicine and application thereof in tumor immunotherapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110263141.2A CN113018433B (en) | 2021-03-11 | 2021-03-11 | Immune medicine and application thereof in tumor immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113018433A true CN113018433A (en) | 2021-06-25 |
CN113018433B CN113018433B (en) | 2023-01-17 |
Family
ID=76469486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110263141.2A Active CN113018433B (en) | 2021-03-11 | 2021-03-11 | Immune medicine and application thereof in tumor immunotherapy |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113018433B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115887695A (en) * | 2022-12-23 | 2023-04-04 | 武汉大学 | Construction method of targeting DNA macromolecule hydrogel material |
CN115887695B (en) * | 2022-12-23 | 2024-05-24 | 武汉大学 | Construction method of targeting DNA high molecular hydrogel material |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105283201A (en) * | 2013-03-14 | 2016-01-27 | 加州生物医学研究所 | Targeting agent antibody conjugates and uses thereof |
CN110494563A (en) * | 2017-01-30 | 2019-11-22 | 奥菲尔·努斯鲍姆 | Chemical entities suitable for treatment |
CN110790841A (en) * | 2019-11-11 | 2020-02-14 | 国家纳米科学中心 | Protein nucleic acid compound and preparation method and application thereof |
CN112336872A (en) * | 2020-08-04 | 2021-02-09 | 华南理工大学 | Nano-aptamer for multi-specific antibody delivery and application and construction method thereof |
-
2021
- 2021-03-11 CN CN202110263141.2A patent/CN113018433B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105283201A (en) * | 2013-03-14 | 2016-01-27 | 加州生物医学研究所 | Targeting agent antibody conjugates and uses thereof |
CN110494563A (en) * | 2017-01-30 | 2019-11-22 | 奥菲尔·努斯鲍姆 | Chemical entities suitable for treatment |
CN110790841A (en) * | 2019-11-11 | 2020-02-14 | 国家纳米科学中心 | Protein nucleic acid compound and preparation method and application thereof |
CN112336872A (en) * | 2020-08-04 | 2021-02-09 | 华南理工大学 | Nano-aptamer for multi-specific antibody delivery and application and construction method thereof |
Non-Patent Citations (2)
Title |
---|
KLAUS N. LOVENDAHL等: "Sequence-Directed Covalent Protein−DNA Linkages in a Single Step Using HUH-Tags", 《J. AM. CHEM. SOC.》 * |
MARGHERITA PASSARIELLO等: "Novel Human Bispecific Aptamer–Antibody Conjugates for E cient Cancer Cell Killing", 《CANCERS》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115887695A (en) * | 2022-12-23 | 2023-04-04 | 武汉大学 | Construction method of targeting DNA macromolecule hydrogel material |
CN115887695B (en) * | 2022-12-23 | 2024-05-24 | 武汉大学 | Construction method of targeting DNA high molecular hydrogel material |
Also Published As
Publication number | Publication date |
---|---|
CN113018433B (en) | 2023-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109476718A (en) | The combination of MRNA and application thereof of encoding immune adjusting polypeptide | |
CN105177031B (en) | T cell of Chimeric antigen receptor modification and application thereof | |
Ma et al. | Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field | |
JP2019519516A (en) | MRNA combination therapy for the treatment of cancer | |
EP3360893A1 (en) | High-affinity and soluble pdl-1 molecule | |
WO2021083363A1 (en) | High-affinity tcr for kras g12v recognition | |
CN109620956B (en) | Intelligent macrophage tumor targeted therapy system and preparation method and application thereof | |
CN110478322B (en) | Nucleic acid drug compound and preparation method and application thereof | |
CN106795517A (en) | Composition based on RNA and for preventative and therapeutic treatment adjuvant | |
CN104244928A (en) | Magnetic nanoparticle-samirna complex and method for preparing same | |
CN112675202A (en) | Anti-tumor immune cell based on targeting ligand cell coupling technology and preparation method and application thereof | |
US11331365B2 (en) | Multispecific protein drug and library thereof, preparing method therefor and application thereof | |
CN111218443B (en) | Method for synthesizing nucleic acid drug conjugates | |
WO2021204287A1 (en) | High-affinity tcr for recognizing hpv16 | |
KR20200078303A (en) | Novel dna aptamer and its uses | |
CN113018433B (en) | Immune medicine and application thereof in tumor immunotherapy | |
CN113018432B (en) | Preparation method of immune medicine | |
WO2021043284A1 (en) | High-affinity t cell receptor that recognizes ssx2 | |
WO2010049375A1 (en) | Use of bacteria for the sensing and killing of cancer cells | |
WO2021036924A1 (en) | High-affinity tcr for recognizing ssx2 antigen | |
CN115998851A (en) | Individuation mRNA composition, vector, mRNA vaccine and application thereof | |
EP3844177A1 (en) | Combination therapies | |
WO2021185368A1 (en) | High-affinity tcr for recognizing afp antigen | |
WO2021023116A1 (en) | High affinity t-cell receptor capable of identifying ny-eso-1 antigen | |
CN114539385A (en) | TCR (T cell receptor) for identifying HPV (human papillomavirus) antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |